Mrs Amy Gates Nevin, MD | |
3174 Beechwood Dr, Allison Park, PA 15101-1160 | |
(412) 608-5259 | |
Not Available |
Full Name | Mrs Amy Gates Nevin |
---|---|
Gender | Female |
Speciality | Pediatrics |
Location | 3174 Beechwood Dr, Allison Park, Pennsylvania |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1336193036 | NPI | - | NPPES |
0018934920003 | Medicaid | PA | |
0018934920004 | Medicaid | PA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208000000X | Pediatrics | MD074436L (Pennsylvania) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Amy Gates Nevin, MD 3174 Beechwood Dr, Allison Park, PA 15101-1160 Ph: (412) 608-5259 | Mrs Amy Gates Nevin, MD 3174 Beechwood Dr, Allison Park, PA 15101-1160 Ph: (412) 608-5259 |
News Archive
A new study from Uppsala University, Sweden, shows that one night of sleep deprivation increases morning blood concentrations of NSE and S-100B in healthy young men. These molecules are typically found in the brain.
COVID-19 patients are at least three times more likely to experience complications if they also have gum disease, according to research published today in the Journal of Clinical Periodontology, the official publication of the European Federation of Periodontology.
Israeli investigators have found that Ashkenazi Jewish women with ovarian cancer who have mutations in the BRCA1 or BRCA2 genes lived significantly longer than Ashkenazi Jewish ovarian cancer patients without these mutations.
"Behaviors such as poor diet choices, physical inactivity, excess alcohol consumption and unhealthy body weight could account for more than 20 percent of cancer cases, and could, therefore, be prevented with lifestyle modifications," Kohler said, adding that when tobacco exposure is considered, these modifiable issues are believed to be factors in two-thirds of U.S. cancer deaths.
Celsion Corporation, a biotechnology drug development company, today announced financial results for the second quarter and six months ended June 30, 2010 and addressed the progression of the clinical trials of ThermoDox, Celsion's heat activated liposomal encapsulation of doxorubicin. ThermoDox is currently being evaluated in the Phase III HEAT trial for the treatment of hepatocellular carcinoma and in a Phase I/II trial for patients with recurrent chest wall breast cancer.
› Verified 6 days ago